Alcon Shares Rise After Dry-Eye Care Drug Shows Promising Results
By David Sachs
Shares in Alcon rose Wednesday after the Swiss company reported positive results for a dry-eye disease treatment undergoing two trials.
At 0834 GMT, Swiss shares of Alcon were up 4.8% at CHF69.46. They had risen as high as CHF70.20
The Swiss eye-care company said late Tuesday that it achieved its primary goals with statistical significance for AR-15512, a candidate to treat dry-eye disease. It plans to file a new drug application with the U.S. Food and Drug Administration in mid-2024, it said.
The drug works demonstrably faster than competitors Restasis and Xiidra, positioning it to grab a significant piece of the U.S. market, Citi analysts said in a research note on Wednesday. Analysts estimated an earnings-per-share upside of around 3% for every $100 million in sales by 2026. The dry-eye treatment market in the U.S., where Alcon is also listed, is worth between $1.5 billion and $2 billion, Citi said.
Alcon also met secondary goals, including rapid and sustained tear production, it said.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
January 10, 2024 03:57 ET (08:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters